US 2022/0088015 A1 · METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED CARDIOMETABOLIC DISEASES

Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases

AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris Est Creteil Val De Marne, Assistance Publique-HôPitaux De Paris (Aphp), Osaka University

InventorsGeneviève DERUMEAUX, Daigo SAWAKI, Gabor CZIBIK, Takehiko YOSHIMITSU

Life of this patent

Estimating the term…

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. The inventors identified osteopontin (OPN) as a critical mediator of adipose tissue remodeling and senescence in obesity and extends this observation to related co-morbidities such as cardiomyopathy. Said result raises the possibility that inhibition of OPN activity may be of value in the prevention of cardiometabolic disease, in particular metabolic cardiomyopathy for which no specific treatment is yet available. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor.

Claims6

Dependent claims

A method of treating at least one symptom of an age-related metabolic cardiomyopathy in an elderly subject in need thereof comprising

administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor, wherein
the therapeutically effective amount is sufficient to treat the age-related metabolic cardiomyopathy,
the OPN inhibitor specifically inhibits the activity or expression of osteopontin, and
the osteopontin (OPN) inhibitor is A (AA).

1 more element

Dependencies are inferred from the claim text.

Facts

Application

17/463,664Filed 1 Sep 2021

Priority

EP 16305397.86 Apr 2016

Published

24 Mar 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 31/498
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines